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Abstract
Background: Duchenne muscular dystrophy (DMD) is an X-linked recessive disease that occurs in males leading to
immobility and death in early adulthood. Female carriers of DMD are generally asymptomatic, yet frequently
develop dilated cardiomyopathy. This study aims to detect early cardiac manifestation in DMD using cardiovascular
magnetic resonance (CMR) and to evaluate its association with clinical symptoms.
Methods: Clinical assessment of DMD carriers included six minutes walk tests (6MWT), blood analysis,
electrocardiography, echocardiography, and CMR using FLASH sequences to detect late gadolinium
enhancement (LGE). T1-mapping using the Modified Look-Locker Inversion recovery (MOLLI) sequence was
performed quantify extracellular volume (ECV).
Results: Of 20 carriers (age 39.47 ± 12.96 years) 17 (89.5 %) were clinically asymptomatic. ECV was mildly
elevated (29.79 ± 2.92 %) and LGE was detected in nine cases (45 %). LGE positive carriers had lower left
ventricular ejection fraction in CMR (64.36 ± 5.78 vs. 56.67 ± 6.89 %, p = 0.014), higher bothCK (629.89 ± 317.48 vs.
256.18 ± 109.10 U/l, p = 0.002) and CK-MB (22.13 ± 5.25 vs. 12.11 ± 2.21 U/l, p = 0.001), as well as shorter walking
distances during the 6MWT (432.44 ± 96.72 vs. 514.91 ± 66.80 m, p = 0.037). 90.9 % of subjects without LGE had
normal pro-BNP, whereas in 66.7 % of those presenting LGE pro-BNP was elevated (p = 0.027). All individuals without
LGE were in the NYHA class I, whereas all those in NYHA classes II and III showed positive for LGE (p = 0.066).
Conclusions: Myocardial involvement shown as LGE in CMR occurs in a substantial number of DMD carriers; it is
associated with clinical and morphometric signs of incipient heart failure. LGE is thus a sensitive parameter for the early
diagnosis of cardiomyopathy in DMD carriers.
Trial registration: Clinicaltrials.gov, NCT01712152 Trial registration: October 19, 2012.
First patient enrolled: September 27, 2012 (retrospectively registered).
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Background
Duchenne Muscular Dystrophy (DMD) is an X-linked
recessive myodegenerative disease that is manifest in
males from early childhood onwards [1, 2] owing to the
absence or vast reduction of dystrophin. DMD patients
suffer from progressive muscle weakness and are wheel-
chair bound by their teens. The majority of DMD pa-
tients die prematurely in their twenties. Involvement of
the cardiac muscle is common, but often remains clinic-
ally silent for want of physical exertion. Corticosteroids
have been found to delay loss of ambulation [3], but to
date no cure has been found for the disease despite on-
going clinical trials.
Female carriers of DMD are often asymptomatic, but
may also display skeletal muscle weakness and may have
elevated CK blood levels. The exact prevalence is un-
known, because most cases only come to light during
diagnostic examinations related to a diseased family
member. Given the longevity factor, myocardial involve-
ment in carriers is clinically more relevant than in DMD
patients: in 10 % of all carriers heart failure in the ab-
sence of skeletal muscle involvement is detected [4, 5],
as compared to 1–2 % in the general population [6]. Fur-
thermore, dystrophy of cardiomyocytes precedes the on-
set of clinical symptoms the result being that signs of
cardiomyopathy (CMP) only come to the fore after sig-
nificant cardiac function impairment has been con-
firmed. The American Academy of Paediatrics (AAP)
thus recommends that every 5 years DMD-carriers
undergo a cardiological examination that includes an
ECG and echocardiography of DMD carriers every 5
years [5]. According to the guidelines issued by the
European Society of Cardiology (ESC) medical therapy
is indicated in cardiomyopathies of any origin in the
event of symptoms or signs of heart failure. In DMD
this refers basically to reduced left ventricular function
(LVF) measured during echocardiography [6]. Standard
medical treatment for heart failure has been success-
fully implemented in DMD patients [7–9], whereas
data on the effectiveness of the same medication in
DMD carriers are insufficient.
Cardiovascular magnetic resonance (CMR) permits
non-invasive depiction of pathological changes in the
myocardial structure such as fibrosis, oedema and fatty
replacement of myocytes [10]. It has, thus, also been
used to assess cardiac involvement in dystrophinopathies
[11, 12]. DMD-patients display a diffuse distribution of
intramyocardial fibrosis, as indicated by late gadolinium
enhancement (LGE) on CMR [13]. There are some
reports on DMD carriers with a similar pattern of
disease even in absence of left ventricular dysfunction
[14–16]. However, diffuse myocardial fibrosis often
passes undetected during LGE analysis. Recent studies
have proposed contrast-enhanced T1-mapping as a
novel tool for determining diffuse fibrosis via CMR in
non-ischemic cardiomyopathies [17–19].
Thus, the aim of our study was to: (i) assess the inci-
dence of myocardial involvement in DMD-carriers using
CMR; (ii) determine a pattern of focal and diffuse myo-




DMD-carriers listed in the data base of the Gottfried
von Preyer Children’s Hospital, an Austrian tertiary re-
ferral centre for neuromuscular diseases in children,
were invited to participate in the study after giving writ-
ten informed consent. Age, body weight and height were
recored and the body surface area and body mass index
were calculated. The patient’s medical records were used
to determine the type of genetic mutation.
The inclusion criteria were: genetic and/or histological
identification as a carrier of DMD; aged 18 years and
above; provision in writing of informed consent; and a
negative pregnancy test in women of childbearing poten-
tial. The exclusion criteria were: claustrophobia; exces-
sive obesity to an extent that precluded performance of
CMR; chronic renal failure with a GFR <30 ml/min/
1,73 m2; implanted pacemakers/defibrillators or other
conditions precluding the carriers from CMR assess-
ment; severe arrhythmia; and inability to cooperate dur-
ing CMR.
Blood sampling
Prior to CMR, venous blood was drawn to determine
blood count and blood chemistry, especially creatine-
kinase (CK), creatine-kinase MB (CK-MB), creatinine,
glomerular filtration rate and pro-brain natriuretic pep-
tide (pro-BNP).
Echocardiography
Echocardiography was performed using scanners (Vivid
7, GE Healthcare) with a 3.5-MHz transducer in stand-
ard imaging planes. Systolic LVF was measured using
biplane Simpson’s method, while diastolic LVF was
assessed by using the inflow signal at the mitral valve
and by tissue Doppler imaging. Diastolic dysfunction
was considered to be present if at least half of the
following parameters exceeded their respective cut-off
value: septal e’ < 7 cm/s, lateral e’ < 10 cm/s, average
E/e’ ratio > 14, left atrium volume index > 34 ml/m2,
tricuscpid regurgitation velocity > 2,8 m/s [20]. Valvu-
lar function was evaluated by means of 2D images
and colour-coded Doppler.
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Cardiac magnetic resonance (CMR)
All patients underwent CMR examinations on a 1.5 T
scanner (MAGNETOM Avanto, Siemens Healthcare
GmbH, Erlangen, Germany). The tests comprised stand-
ard protocols including LGE (0.1 mmol/kg gadobutrol
[Gadovist®; Bayer Vital GmbH, Leverkusen, Germany]) if
the eGFR was >30 ml/min/1.73 m2. Left and right atrial
volumes were assessed using the biplane area-length
method. At the time of inserting the intravenous can-
nula, blood was drawn for the measurement of haemato-
crit and serum creatinine levels. LGE was measured on
short axis stacks using a semi-automatic approach set
at a threshold of five standard deviations above the
mean signal intensity of healthy myocardium.
T1-mapping was performed using electrocardiographi-
cally triggered MOLLI based on a 5(3) 3 prototype (five
acquisition heartbeats are followed by three recovery
heartbeats and a further three acquisition heartbeats) on
a short axis mid-cavity slice and a four-chamber view.
This method generates an inline, pixel-based T1 map
by acquiring a series of images over several heartbeats
with shifted T1 times, inline motion correction and
inline calculation of the T1 relaxation curve during one
breath-hold. The T1 sequence parameters were: starting
inversion time (TI) 120 ms; TI increment 80 ms; recon-
structed matrix size 256 × 218; and measured matrix
size 256 × 144 (phase encoding resolution 66 %, phase
encoding field of view 85 %). T1 maps were created
both before and 15 min after the application of the con-
trast agent. For post contrast T1-mapping, a 4(1) 3(1) 2
prototype was used. Regions of interest were defined as
left ventricular myocardium without LGE in order to
study the prognostic impact of diffuse extracellular
matrix expansion that could not be detected during
visual assessment. T1 values (ms) of the blood pool
were obtained at a sufficient distance from the papillary
muscles and the endomyocardial border. Mean T1
values from the short axis and the four-chamber view
were calculated CMR-ECV was calculated using the
formula [21]:










− 1T1 blood pre
 
where “T1 myo pre”/“T1 blood pre” indicates myocar-
dial/blood native T1 times and “T1 myo post”/“T1 blood
post” indicates T1 times of myocardium/blood 15 min
after application of the contrast agent. ECV was consid-
ered normal ≤28.5 % [22]. We used a dedicated software
(cmr42, Circle Cardiovascular Imaging Inc., Calgary,
Alberta, Canada) for further CMR analysis.
The ventricular function was determined on short axis
stacks using Simpson’s rule. The epicardial border of the
left ventricle was traced in order to determine ventricu-
lar mass, multiplying the wall volume by the specific
density of the myocardium (1,05 g/cm3).
Study visits
At each visit blood was drawn to determine the parame-
ters mentioned above and the patients underwent clin-
ical examination. The clinical stage was recorded
according to the New York Heart Association (NYHA)
classification. Echo (P.W.) and CMR (B.F., S.P.) analyses
were performed by experienced observers blinded to the
pro-BNP values. All patients were scheduled for a
follow-up examination 12 months later. If clinically indi-
cated, additional follow-up examinations (clinical, echo-
cardiography, CMR) were performed. In symptomatic
patients with signs of myocardial involvement medical
therapy of heart failure was initiated according to the
ESC guidelines for the treatment of heart failure.
Statistical analysis
Statistical analysis was performed using the SPSS
package (SPSS 22, IBM Corp., Armonk, New York,
USA). In normal distribution, data for continuous var-
iables were expressed as mean ± standard deviation
(SD) and intergroup comparisons were carried out
using a two-sided unpaired Student’s t-test. Categor-
ical parameters were compared using the chi-square
test. Numeric changes over time were assessed by a
paired t-test. Differences were considered statistically
significant at a p-value < 0.05.
Results
Baseline
Twenty-two carriers agreed to participate in the study.
CMR could not be performed in two carriers for reasons
of claustrophobia; so they were excluded from the study.
The demographic characteristics of the 20 subjects
remaining (mean age 39.47 ± 12.96 years, range 21 to
62 years) are shown in Table 1. Seventeen of the carriers
included (85.0 %) were clinically asymptomatic, two
were in NYHA class II and one in NYHA III; the latter
also displayed neurological symptoms (weakness of the
thigh muscles).
Overall, mean ECV was mildly elevated (29.79 ±
2.92 %) with abnormal values in 65.0 % of all cases.
These subjects did not differ from those with normal
values in regard to clinical and laboratory parameters of
cardiac function (data not shown). In nine carriers
(45.0 %) LGE was visible in the myocardium of the left
ventricle. This group presented higher septum thick-
ness and lower EF in CMR, had higher systolic blood
pressure, higher blood levels of CK and CK-MB and
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shorter walking distances at 6MWT. 90.9 % (n = 10) of
the subjects without LGE had normal pro-BNP, whereas
66.7 % (n = 6) of those with LGE had elevated pro-BNP
values (p = 0.027). Pro-BNP tended to be higher as well.
As a marker of diffuse myocardial fibrosis ECV did not
differ significantly between patients with and without
LGE (Table 1).
Comparing dyspnea, all 11 individuals without LGE
were in NYHA class I, whereas in all subjects in NYHA
II (n = 2) and III (n = 1) LGE was present (p = 0.066).
Dividing the cohort in those below (n = 13 [65.0 %])
and those above (n = 7 [25.0 %]) the age-corrected cut-
off value of pro-BNP for females, the latter had higher
CK and CK-MB levels and shorter distances covered
during the 6MWT (421.29 ± 105.20 vs. 508.23 ± 66.03 m,
p = 0.035). Septum thickness was higher and ejection
fraction in CMR lower. Systolic blood pressure and ECV
were comparable (Table 2). LGE was present in 85.7 %
of subjects with elevated pro-BNP compared to 23.1 %
in those with normal levels (p = 0.027).
The genetic analysis and the distribution of LGE are
shown in Table 3.
Follow-up
All subjects were alive 12 months after the initial visit
and no major adverse cardiac events were reported.
Only eight subjects came to the scheduled follow-up
examination, seven of whom had had no LGE visible at
the initial CMR examination. The main reasons given
for dropping out of the study were social in origin, relat-
ing to caring for the diseased child and psychological
distress following a son’s death. The data, thus, do not
suffice for purposes of statistical analysis. However, none
of the women with negative CMR developed LGE during
the follow-up period. Overall, no substantial clinically
relevant deterioration was observed and ECV remained
practically unchanged (−1,84 ± 1.81 %); the subject diag-
nosed with LGE during the initial examination (#1)
walked a shorter distance during the 6MWT conducted
at the follow-up examination (163 vs. 210 m), but no
change was detected in terms of pro-BNP, LVF or ECV.
Discussion
Our study showed that ECV is elevated in DMD carriers;
and that LGE is associated with LVF and shorter dis-
tances covered during the 6MWT.
Table 1 Clinical and imaging parameters by LGE
LGE neg. LGE pos. p
Age (ys) 38.65 ± 10.84 41.56 ± 12.23 0.593
BMI (kg/m2) 23.84 ± 2.83 24.14 ± 5.45 0.442
6MWT (m) 514.91 ± 66.80 432.44 ± 96.72 0.037
RR syst (mmHg) 111.18 ± 11.29 127.11 ± 16.86 0.021
RR diast (mmHg) 75.00 ± 10.50 83.56 ± 14.37 0.141
HR (/min) 69.91 ± 11.76 69.67 ± 11.57 0.964
Hkt (%) 37.36 ± 4.42 39.32 ± 3.37 0.298
CK (U/l) 256.18 ± 109.10 629.89 ± 317.48 0.002
CK-MB (U/l) 12.11 ± 2.21 22.13 ± 5.25 0.001
Trop. T (ng/ml) 0.01 ± 0.02 0.02 ± 0.01 0.487
proBNP (ng/l) 80.70 ± 33.84 142.89 ± 93.35 0.088
EF Echo (%) 63.38 ± 7.03 59.75 ± 7.52 0.336
E/A 1.67 ± 0.57 3.91 ± 7.91 0.383
E/e’ 5.21 ± 1.86 6.01 ± 3.59 0.548
IVS Echo (mm) 8.96 ± 0.96 10.44 ± 1.51 0.015
LVEF CMR (%) 64.36 ± 5.78 56.67 ± 6.89 0.014
RVEF CMR (%) 55.45 ± 12.52 57.11 ± 9.24 0.792
T1 native (ms) 1016.73 ± 72.06 994.89 ± 36.32 0.386
ECV (%) 30.77 ± 2.96 28.60 ± 2.55 0.500
6MWT Six minutes walk test, BMI body mass index, BNP brain-natriuretic peptide,
CK creatine phosphokinase, ECV extracellular volume, EF Echo ejection fraction
determined by echocardiography, IVS intraventricular septum determined by
echocardiography, LGE late gadolinium enhancement, LVEF CMR left-ventricular
ejection fraction determined by cardiovascular magnetic resonance, RR syst
systolic blood pressure, RR diast diastolic blood pressure, RVEF CMR right-
ventricular ejection fraction determined by cardiac magnetic resonance, Trop. T
troponin T, T1 native native T1-time of the myocardium
Table 2 Clinical and imaging parameters by pro-BNP
low pro-BNP high pro-BNP p
Age (ys) 38.04 ± 10.75 43.39 ± 12.19 0.324
BMI (kg/m2) 24.6 ± 4.72 22.81 ± 2.46 0.139
6MWT (m) 508.23 ± 66.03 421.29 ± 105.20 0.035
RR syst (mmHg) 117.69 ± 19.12 119.57 ± 8.14 0.809
RR diast (mmHg) 80.54 ± 14.31 75.71 ± 9.60 0.437
HR (/min) 70.08 ± 11.81 69.29 ± 11.37 0.887
Hkt (%) 37.25 ± 4.76 39.59 ± 2.42 0.301
CK (U/l) 323.08 ± 192.54 612.43 ± 363.06 0.030
CK-MB (U/l) 13.45 ± 3.14 23.00 ± 6.36 0.001
Trop. T (ng/ml) 0.01 ± 0.02 0.02 ± 0.01 0.392
EF Echo (%) 61.60 ± 5.58 61.5 ± 10.13 0.980
E/A 3.65 ± 6.74 1.16 ± 0.35 0.348
E/e’ 5.47 ± 2.28 5.77 ± 3.66 0.832
IVS Echo (mm) 9.04 ± 1.23 10.71 ± 1.11 0.008
LVEF CMR (%) 63.54 ± 5.95 56.00 ± 7.35 0.023
RVEF CMR (%) 56.46 ± 5.61 56.00 ± 5.57 0.085
T1 native (ms) 1014.69 ± 64.00 992.43 ± 43.39 0.370
ECV (%) 30.03 ± 2.97 29.36 ± 3.02 0.642
6MWT Six minutes walk test, BMI body mass index, BNP brain-natriuretic peptide,
CK creatine phosphokinase, ECV extracellular volume, EF Echo ejection fraction
determined by echocardiography, IVS intraventricular septum determined by
echocardiography, LGE late gadolinium enhancement, LVEF CMR left-ventricular
ejection fraction determined by cardiovascular magnetic resonance, RR syst
systolic blood pressure, RR diast, diastolic blood pressure, RVEF CMR, right-
ventricular ejection fraction determined by cardiovascular magnetic resonance,
Trop. T troponin T, T1 native native T1-time of the myocardium
Wexberg et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:61 Page 4 of 8
Reviewing the literature, very limited data exists on
the natural history of carriers of DMD. Prognostic pre-
dictors are therefore difficult to detect. In general, a
broad variety of symptoms is to be found in female con-
ductors, which, in part, can be explained by chromo-
some X inactivation [23, 24]. In general the clinical
presentation is much less dramatic than in male pa-
tients. In a cohort study performed in the Netherlands
22 % of the carriers displayed muscle weakness of vary-
ing severity, eight per cent had dilated cardiomyopathy
and asymptomatic dilatation of the left ventricle was
present in 18 % [25]. CMR studies indicate that fibrosis
is involved in myocardial involvement in dystrophino-
pathies [13–16]; this appears to be a consequence of
the same mechanisms observed in skeletal muscles
[25]: Cardiomyocyte membranes are disrupted owing
to the lack of dystrophin and a subsequent increase in
intracellular concentration of calcium [26]. That leads
to an activation of calcium-dependent proteases result-
ing in changes to the muscle cell membrane, the
cycoskeleton and myofibrillae and ultimately to cell
necrosis [27–30]. The increase in endo- and perimysial
connective tissue leads to progressive fibrotic degener-
ation [31, 32] and clinically to the typical inevitable
immobilisation and demise of the patients.
In our cohort 45 % of the carriers displayed morpho-
logical signs of myocardial involvement. While the de-
tection of LGE and the influence on systolic LVF is in
accordance with findings in recent publications [33–36]
an association with clinical presentation has not been
shown yet [36]. We found a statistically significant dif-
ference in cardiovascular and musculoskeletal parame-
ters such as contraction of the distance walked during
the 6MWT and higher blood levels of CK and CK-MB,
as well as a trend towards higher pro-BNP levels and
higher NYHA class in the presence of LGE. Systolic
blood pressure was also higher in this particular group,
so that one might speculate as to a haemodynamic con-
founding effect. However, only two of the subjects in
the group with LGE (#8, #20) had hypertension (160/
110 mmHg and 147/102 mmHg, respectively) further
to which when classifying the probands according to
their pro-BNP values blood pressure levels were com-
parable. Thus, our findings tend to suggest a correl-
ation between the extent of myocardial involvement
and clinical presentation.
Given the underlying pathogenetic process myocar-
dial fibrosis is a dynamic process. A recent longitudinal
study of 98 DMD-patients with at least four CMR as-
sessments established that 52 % developed LGE during
Table 3 Mutations and presence of LGE and LVEF
Patient Age (ys) Mutation LGE LGE location LGE distribution # segments LVEF (%)
1 42 del. exon 12–29 + inf, lat end, mid 3 54
2 40 del. 48–50 - - - 0 58
3 38 point mutation intron 40 - - - 0 72
4 40 exon 48 (somatic mosaic) - - - 0 70
5 24 n. k. + inf, lat mid 6 42
6 26 dupl. exon 3–34 + inf, lat mid 2 58
7 62 n. k. + inf, lat mid 4 64
8 38 nonsense mutation exon 12 + lat mid 1 65
9 55 n. k. + ant, lat mid 6 57
10 39 n. k. + lat epi 2 53
11 41 n. k. - - - 0 61
12 29 dupl. exon 1–2 and 39–34 - - - 0 66
13 59 dupl. exon 1–2 and 39–34 - - - 0 74
14 22 dupl. exon 1–2 and 39–34 - - - 0 59
15 40 dupl. exon 1–2 and 39–34 - - - 0 61
16 34 del. exon 23 - - - 0 57
17 41 point mutation exon 24 + lat mid, epi 3 61
18 29 del. exon 44 - - - 0 66
19 53 del. exon 1–11 - - - 0 64
20 47 del. exon 43 + ant, lat mid 2 56
ant anterior, del. deletion, dupl. duplication, end subendocardial, epi subepicardial, inf inferior, lat lateral, LGE late gadolinium enhancement, LVEF left ventricular
ejection fraction (measured by CMR), mid midmyocardial, n. k. not known, # segments number of left ventricular segments involved
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the observation period. The decline in LVF was more
pronounced once LGE had developed [37]. It appears
justified to speculate that a similar development might
occur in DMD-carriers. On account of the broad variety
of mutations, we could not detect any correlation between
the presence of LGE and a specific genotype. Within one
family with the same mutation (duplication of exons 1–2
and 39–34) LGE was not present in either youngest mem-
ber (aged 21) or the oldest (aged 59), however, our cohort
was too small to deduce a clear association.
Owing to their longevity DMD-carriers often develop
heart failure in the absence of classical causes such as is-
chemic or inflammatory heart disease. According to our
data, diastolic dysfunction does not appear to be associ-
ated with LGE according to our data; this is borne out
by the findings of others [35]. Screening for morpho-
logical signs might thus help to detect subjects who are
at risk in terms of developing cardiomyopathy. Given
the predictive value of myocardial fibrosis [22, 37, 38], it
is quite conceivable that the early initiation of neurohu-
moral therapy, the gold standard in the treatment of
heart failure [6], might help to prevent LVF deterior-
ation. Myocardial fibrosis can either be focal, as shown
by LGE, or diffuse, as represented by an elevated ECV.
In our cohort we found focal areas of mid-myocardial
LGE which, for the most part, were located in predom-
inantly lateral and inferolateral wall segments (Table 3,
Fig. 1), thus confirming earlier reports [33–36]. At the
same time CMR T1-mapping also revealed a generally
elevated mean ECV. One might speculate that: (i) in
general, DMD carriers may display diffusely of focally
distributed myocardial fibrosis; or (ii) LGE is an
advanced form of initially diffuse fibrosis. However, the
data do not suffice to support fully this hypothesis.
Study limitations
DMD is a rare disease; its carriers are regularly detected
either fortuitously or in the course of a diseased relative
being examined. In addition, the women so affected have
to bear the burden of witnessing their sons as they pro-
gressively waste away and the responsibility of providing
ever-increasing care. Thus, the number of subjects who
were willing to participate fully in our study was low. In
particular, it proved impossible in most cases to conduct
the follow-up examinations scheduled for 12 months
later. Such a small cohort also excluded special statistical
applications (e.g. multivariate analysis) that would have
permitted correction for confounders.
A larger cohort might have also provided a a firmer
basis on which to assess a possible correlation between
genotype and phenotype. In five carriers no mutation
was detected; however, given the histological confirm-
ation of DMD those carriers underwent further analysis.
Progression of myocardial fibrosis might be a slow
process and a longer clinical follow-up might be neces-
sary as to permit a prognostic interpretation of our find-
ings and allow for the dynamic changes in diffuse and
focal presentations.
Fig. 1 Diffuse myocardial fibrosis. Short-axis view (inversion-recovery
gradient-echo) depicting diffuse myocardial fibrosis in two carriers
of DMD. Note the patchy pattern of LGE along the lateral and
inferolateral wall
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To date, no precise normative values have been deter-
mined for ECV. However, on applying the highest tertile
of Wong et al. [22] we have recently been able to demon-
strate a prognostic impact of ECV [38]. That cut-off value
was therefore applied throughout the present study.
Conclusions
On using CMR, a substantial proportion of the DMD-
carriers examined displayed signs of myocardial fibrosis
which is associated with clinical parameters. Screening
for early morphological signs of myocardial involvement
may be potentially useful in the detection of subjects at
risk of developing heart failure. CMR with an LGE-study
should be performed during the diagnostic examination
of this cohort. In further studies, the longitudinal devel-
opment of myocardial fibrosis should be evaluated. It
remains to be clarified in long-term studies whether the
presence of LGE is an indication of the need to start
specific neurohumoral medication.
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